Exploiting DNA repair defects in breast cancer : from chemotherapy to immunotherapy
Introduction: Impaired DNA damage response (DDR) and subsequent genomic instability are associated with the carcinogenic process itself, but it also results in sensitivity of tumor cells to certain drugs and can be exploited to treat cancer by inducing deadly mutations or mitotic catastrophe. Exploiting DDR defects in breast cancer cells has been one of the main strategies in both conventional chemotherapy, targeted therapies, or immunotherapies. Areas covered: In this review, the authors first discuss DDR mechanisms in healthy cells and DDR defects in breast cancer, then focus on current therapies and developments in the treatment of DDR-deficient breast cancer. Expert opinion: Among conventional chemotherapeutics, platinum-based regimens, in particular, seem to be effective in DDR-deficient patients. PARP inhibitors represent one of the successful models of translational research in this area and clinical data showed high efficacy and reasonable toxicity with these agents in patients with breast cancer and BRCA mutation. Recent studies have underlined that some subtypes of breast cancer are highly immunogenic. Promising activity has been shown with immunotherapeutic agents, particularly in DDR-deficient breast cancers. Chemotherapeutics, DNA-repair pathway inhibitors, and immunotherapies might result in further improved outcomes in certain subsets of patients with breast cancer and DDR.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
Expert review of anticancer therapy - 19(2019), 7 vom: 29. Juli, Seite 589-601 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Aktas, Burak Yasin [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antineoplastic Agents |
|---|
| Anmerkungen: |
Date Completed 20.03.2020 Date Revised 20.03.2020 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/14737140.2019.1631162 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM297990403 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM297990403 | ||
| 003 | DE-627 | ||
| 005 | 20231225093207.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/14737140.2019.1631162 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0993.xml |
| 035 | |a (DE-627)NLM297990403 | ||
| 035 | |a (NLM)31181965 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Aktas, Burak Yasin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Exploiting DNA repair defects in breast cancer |b from chemotherapy to immunotherapy |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.03.2020 | ||
| 500 | |a Date Revised 20.03.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Introduction: Impaired DNA damage response (DDR) and subsequent genomic instability are associated with the carcinogenic process itself, but it also results in sensitivity of tumor cells to certain drugs and can be exploited to treat cancer by inducing deadly mutations or mitotic catastrophe. Exploiting DDR defects in breast cancer cells has been one of the main strategies in both conventional chemotherapy, targeted therapies, or immunotherapies. Areas covered: In this review, the authors first discuss DDR mechanisms in healthy cells and DDR defects in breast cancer, then focus on current therapies and developments in the treatment of DDR-deficient breast cancer. Expert opinion: Among conventional chemotherapeutics, platinum-based regimens, in particular, seem to be effective in DDR-deficient patients. PARP inhibitors represent one of the successful models of translational research in this area and clinical data showed high efficacy and reasonable toxicity with these agents in patients with breast cancer and BRCA mutation. Recent studies have underlined that some subtypes of breast cancer are highly immunogenic. Promising activity has been shown with immunotherapeutic agents, particularly in DDR-deficient breast cancers. Chemotherapeutics, DNA-repair pathway inhibitors, and immunotherapies might result in further improved outcomes in certain subsets of patients with breast cancer and DDR | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Breast cancer | |
| 650 | 4 | |a DNA damage response | |
| 650 | 4 | |a PARP inhibitor | |
| 650 | 4 | |a immunotherapy | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Poly(ADP-ribose) Polymerase Inhibitors |2 NLM | |
| 700 | 1 | |a Guner, Gurkan |e verfasserin |4 aut | |
| 700 | 1 | |a Guven, Deniz Can |e verfasserin |4 aut | |
| 700 | 1 | |a Arslan, Cagatay |e verfasserin |4 aut | |
| 700 | 1 | |a Dizdar, Omer |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert review of anticancer therapy |d 2001 |g 19(2019), 7 vom: 29. Juli, Seite 589-601 |w (DE-627)NLM11982020X |x 1744-8328 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2019 |g number:7 |g day:29 |g month:07 |g pages:589-601 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/14737140.2019.1631162 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2019 |e 7 |b 29 |c 07 |h 589-601 | ||